BioCentury | Sep 10, 2020
Product Development

Oxford’s Landray wants RECOVERY-type trials to go well beyond COVID-19: a BioCentury audio interview

...trial of -- let's say -- a PCSK9...
...a target -- you've just talked about PCSK9...
BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

...based on cardiovascular outcomes. That is the likely path for another therapy as well: inclisiran, a PCSK9-targeted...
...a stake in its success.TARGETSACLY – ATP citrate lyaseCETP – Cholesteryl ester transfer proteinPCSK9Proprotein convertase subtilisin/kexin type 9 Paul...
BioCentury | Jul 10, 2020
Finance

More risk-sharing deals to come from Blackstone's inaugural $4.6B life sciences fund, plus earlier investments

...NASDAQ:ALNY) via a deal that included a $1 billion royalty and commercial milestone purchase around PCSK9-targeting...
...$337 million to Medtronic plc (NYSE:MDT) to develop tools for diabetes management. Targets PCSK9 - Proprotein convertase subtilisin/kexin type 9 Virginia...
BioCentury | Jun 11, 2020
Finance

Insiders lead, crossovers join in gene editing play Verve’s $63M round

...pathways, all of which can be accessed in the liver. Among the genes involved are PCSK9...
...prior to his arrival at Verve. Other lipid-lowering approaches involving those targets have included marketed PCSK9...
...stealth mode. Targets ANGPTL3 - Angiopoietin-like 3 PCSK9 - Proprotein convertase subtilisin/kexin type 9 Paul Bonanos, Associate Editor Verve Therapeutics Inc. GV Proprotein convertase subtilisin/kexin type 9 (PCSK9) Angiopoietin-like...
BioCentury | May 27, 2020
Deals

Sanofi's sale of Regeneron stake for $11B could set stage for both companies' growth through M&A

...VEGF fusion protein Zaltrap aflibercept; rheumatoid arthritis treatment Kevzara sarilumab; atopic dermatitis therapy Dupixent dupilumab; anti-PCSK9...
...cervical cancer, and to treat head and neck cancer. Targets IL-2 - Interleukin-2 PCSK9 - Proprotein convertase subtilisin/kexin type 9...
BioCentury | May 23, 2020
Translation in Brief

A three-compound dengue treatment; plus reversing antibiotic resistance, AbCellera-Lilly, reducing cholesterol with CRISPR and COVID cash for Sherlock

...nanoparticles to a hepatocyte-targeted ligand. Mice injected with the PCSK9-targeting nanoparticles had serum reductions in PCSK9...
...PCSK9 - Proprotein convertase subtilisin/kexin type 9 Danielle Kopke, Staff Writer, and Robin Sawka, Biocentury Staff Sherlock Biosciences Inc. Open Philanthropy Project Stanford University Proprotein convertase subtilisin/kexin type 9...
...Proprotein convertase subtilisin/kexin type 9 Danielle Kopke, Staff Writer, and Robin Sawka, Biocentury Staff Sherlock Biosciences Inc. Open Philanthropy Project Stanford University Proprotein convertase subtilisin/kexin type 9 (PCSK9) CRISPR...
BioCentury | Apr 14, 2020
Finance

Blackstone makes largest-ever life sciences investment in Alnylam

...in Alnylam. The deal includes a $1 billion royalty and commercial milestone purchase around the PCSK9-targeting...
...again,” said Maraganore. “This is our nondilutive path forward for our shareholders.” Targets PCSK9 - Proprotein convertase subtilisin/kexin type 9 Lauren...
BioCentury | Feb 22, 2020
Product Development

Esperion enters crowded LDL-lowering market with FDA approval

...Praluent alirocumab from Sanofi (Euronext:SAN; NASDAQ:SNY) and Repatha evolocumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), both PCSK9...
...widely considered one of the factors behind their slow uptake. Behind Nexletol is inclisiran, a PCSK9-targeted...
...company lost $6.59 (10%) to $61.76 Friday. Targets ACLY - ATP citrate lyase PCSK9 - Proprotein convertase subtilisin/kexin type 9 Hongjiang...
BioCentury | Feb 14, 2020
Finance

On heels of reimbursement, Innovent raises $303M to ready Tyvyt rollout

...launch of additional drugs in the next few years. Innovent’s late-stage pipeline includes IBI306, an anti-PCSK9...
...1 PCSK9 - Proprotein convertase subtilisin/kexin type 9 Hongjiang Li, Staff Writer Tyvyt, sintilimab (IBI308) Programmed cell death 1 (PD-1) (PDCD1) (CD279) Proprotein convertase subtilisin/kexin type 9 (PCSK9) IBI306...
BioCentury | Jan 29, 2020
Company News

Launches fuel Novartis’ growth as CEO reiterates China commitment

With over 90% commercial payer coverage for SMA gene therapy Zolgensma and increased uptake for heart failure drug Entresto, Novartis posted nearly double-digit sales growth in 2019 as the pharma looks to additional new drugs...
Items per page:
1 - 10 of 517